RSS | Print | PDF | Email Page


Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog

August 2017

Visit the Jones Day PTAB Litigation Blog.

At least 19 IPRs have been filed against seven of Genentech’s patents covering its blockbuster antibody drug Herceptin® (trastuzumab). On July 27, 2017, the PTAB instituted IPRs filed by Hospira, Inc. (a subsidiary of Pfizer) against three Herceptin® patents, and denied an IPR for a fourth Herceptin® patent.

The four challenged patents (U.S. Patent Nos. 6,627,196; 7,371,379; 7,846,441; and 7,892,549) belong to two different families, with one family covering the use of Herceptin® in combination therapies and the other covering dosing regimens for treating disorders characterized by overexpression of ErbB2.

Read the full article at


Areas of Concentration